CONTEXT: Report from the European Hematology Association Annual Meeting on a real-world study looking at uses of axicabtagene ciloleucel (Yecarta) and tisagenleucel Kymriah). A review of 93 patients in the US revealed the CAR-T cell therapies are predominantly used to treat diffuse b-cell lymphoma (DLBCL).
IMPACT: Low
READ TIME: 1 min
Quality Level Mean [1 – 10]: 7
1. “Commercial insurance was the primary payer during the time of therapy on either tisa-cel or axi-cel for 83% of patients with DLBCL, followed by 12% on Medicare, 3.2% on Medicaid, and 1 patient was unknown.”
2. “In the first few years of their availability in the United States, axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (tisa-cel; Kymriah) have been used to mostly treat patients with diffuse large b-cell lymphoma (DLBCL) in the outpatient setting who are receiving the CAR T-cell therapies prior to failure on 2 prior lines of therapy, according to findings from a real world study presented at the virtual European Hematology Association Annual Meeting.1. Looking at a total of 93 patients with DLBCL, 58% (n = 54) received axi-cel and 42% (n = 39) received tisa-cel, the majority of which (59%) received either CAR T-Cell therapy in the outpatient setting, compared to 40% in inpatient care.”
3. “In a median follow up of 6.3 months, 45% of patients received either 2 or more lines of systemic therapy prior to receiving tisa-cel or axi-cel, while 17% received their systemic therapy after the CAR T-cell therapy.”
4. “Following CAR T-cell therapy, 82.8% did not receive therapy, 10.8% had 1 therapy after CAR T-cell therapy, and 6.5% had 2 therapies following either tisa-cel or axi-cel.”
5. “Real-World Treatment with CAR T-Cell Therapy of United States (US) Patients with Large B Cell Lymphoma (LBCL).”